Moneycontrol Pro Panorama | For MNC pharma companies, small is beautiful

MNC pharma companies thrive in their chosen product categories, delivering exceptional profit margins and earnings.

Dear Reader,

Multinational pharma companies do not lead league tables in India. Only Abbott features among the top 10 pharma companies by revenue in the domestic market. Yet, MNC pharma companies thrive in their chosen product categories, delivering exceptional profit margins and earnings.

Consider the latest results of Pfizer and GlaxoSmithKline Pharmaceuticals. The companies reported exceptional profit margins of 35.4 percent and 35.9 percent, respectively, in the December 2025 quarter. Market leader Sun Pharma, which had a benefit of non-recurring milestone income in Q3 FY26, reported a profit margin of 31.9 percent.

Not surprisingly, investors are impressed by Pfizer’s and GSK Pharma’s performance. The stocks are up by about 5 percent and 1 percent, respectively, in Tuesday afternoon trade. Profitability at both the companies improved significantly in the past two years. At Pfizer, profit margins increased from about 28 percent in Q3 FY24 to 35.4 percent last quarter. GSK Pharma’s profit margins rose from 27 percent to 35.9 percent during the same period.

The strong profit margins are resulting in robust cash addition and superior return ratios for companies. “Pfizer had ~Rs 2,700 crore (Rs 590/share) cash on its balance sheet which could be used to reward shareholders through significant dividends or M&A,” analysts at ICICI Securities said in a note.

What’s more, the companies are expected to maintain positive momentum in operating performance. Pfizer entered into a supply and distribution agreement with Cipla for four branded products and is expected to benefit from the partnership. Easing supply chain constraints are estimated to aid sales of GSK Pharma.

Both companies focus on branded products, vaccines, OTC products and certain therapeutics categories. In comparison to leading pharma companies in India, Pfizer and GSK Pharma have relatively smaller product portfolios. However, they have strong brands in chosen product categories. This helps them derive superior realisations and profit margins.

GSK Pharma’s anti-infective medication Augmentin regularly tops branded products sales charts in India. You can read our analysis of the Indian pharma market’s performance in January 2026 here.

“Pfizer India holds a strong brand portfolio, a robust balance sheet, and continues to deliver healthy profitability,” analysts at Nirmal Bang Institutional Equities said in a note.

That said, readers may note that Pfizer and GSK Pharma are not particularly known as revenue growth leaders in India. Slow product launches and portfolio additions have resulted in moderate revenue growth rates in the past.

While high profit margins are expected to yield superior earnings performance (versus revenue growth) in the near term, Pfizer and GSK Pharma are trying to improve revenue growth rates by strengthening their product portfolios. Success on this front will help the companies deliver all-round performance and also add heft to their valuations.

Investing insights from our research team

Pidilite Q3 FY26: Steady growth in a mixed demand environment

Emami: Bright growth prospects, appealing valuation

Bosch: Steady Q3 FY26; valuation limits upside

Carysil Q3: Benign raw material costs drive margin expansion

Tracker

Pro Economic Tracker | Auto sales, consumer sentiment decline

What else are we reading?

RBI survey shows a nervous urban consumer, but help is around the corner

Is it time to increase allocation to gold?

RBI passes growth baton to government after Budget, trade deals

Chart of the Day: A steady start to 2026 for Indian pharma market

Personal Finance: To rebalance or not, in uncertain times

The market meltdown in data companies is profoundly wrong (republished from the FT)

The Great Rebalancing: India's opening amidst a fracturing monetary order

How Indian founders without fancy credentials beat pedigreed returnees

India-US interim trade deal signals boost in FDI and technology transfer

The Economics of Love: Irrational, enduring, unanswerable

Economics of Ageing: Why preventive elder care makes fiscal sense

Markets

New demat account openings hit 16-month high in January despite market volatility 

Tech and Startups

Upstox eyes Charles Schwab-style playbook as cofounder Ravi Kumar drives diversification, profitability

Technical Picks: DIVISLAB, KFINTECH, HFCL, TMPV, APOLLOHOSP, AMBER

R Sree Ram

Moneycontrol Pro